Prolight Diagnostics publishes investorletter for January 2026

The investor letter outlines that Prolight has continued to make important progress in the development of the Psyros platform. Progress in cartridge manufacturing scale-up, alongside continued refinement of the instrument design, further strengthens the platform as the company prepares for the commercial launch. 

The investor letter is available via the attached file or on the company’s website:https://prolightdx.com/en/mediaeng/investor-letters/